U.S. Markets close in 1 hr 49 mins

Eisai Co., Ltd. (4523.T)

Tokyo - Tokyo Delayed Price. Currency in JPY
Add to watchlist
9,456.00+315.00 (+3.45%)
At close: 3:15PM JST

Eisai Co., Ltd.

4-6-10, Koishikawa
Bunkyo-ku
Tokyo 112-8088
Japan
81 3 3817 3700
http://www.eisai.co.jp

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees11,237

Key Executives

NameTitlePayExercisedYear Born
Mr. Haruo NaitoCEO, Representative Corp. Officer & Director140MN/A1947
Mr. Gary HendlerSr. VP & Pres of EMEA Region141MN/A1966
Dr. Lynn D. KramerVP & Chief Clinical Officer - Neurology Bus. Group194MN/A1950
Ms. Yanhui FengSr. VP114MN/AN/A
Mr. Nadeem SarwarPresN/AN/AN/A
Mr. Ryohei YanagiExec. VP & CFON/AN/A1962
Ms. Sayoko SasakiChief IR Officer & VPN/AN/A1968
Mr. Mitsuaki TanakaChief Compliance Officer, Internal Control, Chief Information Security Officer & VPN/AN/AN/A
Mr. Yasushi OkadaRepresentative Corp. Officer, COO, Industry Affairs, China Bus. & Data IntegrityN/AN/A1958
Mr. Edward Stewart GearySr. VP & Global Safety OfficerN/AN/A1962
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.

Description

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

Corporate Governance

Eisai Co., Ltd.’s ISS Governance QualityScore as of June 1, 2021 is 4. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 10; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.